Photo: Leonidas Santana/Shutterstock
Developed by the São Paulo-based Butantan Biological Institute, the ButanVac coronavirus vaccine showed “an acceptable safety profile and potent immunogenicity” in clinical trials held in Thailand.
A pre-print version of the study was published by researchers from Bangkok’s Mahidol University, the Icahn School of Medicine at Mount Sinai, and the University of Texas at Austin.
The study shows that “there were no vaccine-related serious adverse events.” The vaccine is also being tested in Brazil and Vietnam, but trial data from the two countries have not been made available so far.
Developed from technology patented by the Icahn School of Medicine, ButanVac was advertised as a way to give Brazilian labs the scale and autonomy needed to speed up the immunization process. But it should only be ready for distribution in later stages of vaccination — almost 70 percent of Brazilians have gotten at least one shot and 40 percent are fully immunized.
The city of Rio de Janeiro estimates that a Madonna concert this Saturday on Copacabana…
Latin America’s trend of banning opposition candidates from elections has caught on in an ever-growing…
The São Paulo City Council on Thursday approved legislation authorizing Brazil’s largest city to sign…
The preliminary report on AI regulations presented to Brazil’s Senate last week provides a middle-of-the-road…
In 2000, Formula 1 great Michael Schumacher had just racked up his 41st race win,…
Overall, the worldwide economic outlook has improved according to the Organization for Economic Co-operation and…